EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Development and Characterization of In Situ Gelling Nasal Cilostazol Spanlastics

Maryana Salamah iD, Mária Budai-Szűcs iD, Bence Sipos iD, Balázs Volk iD, Gábor Katona iD, György Tibor Balogh iD, Ildikó Csóka iD

Gels · 22.01.2025 · 11 (2) · 82

DOI: 10.3390/gels11020082 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Gels, online erschienen am 22.01.2025. Verfasst von Maryana Salamah und 6 weiteren Autor:innen. Beteiligte Einrichtung: Institute of Pharmaceutical Technology and Regulatory Affairs, Faculty of Pharmacy, University of Szeged, Eötvös Str. 6, H-6720 Szeged, Hungary. Die Arbeit wurde bisher 20-mal zitiert (Crossref) und nennt 127 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Ministry of Innovation and Technology of Hungary from the National Research, Development, and Innovation Fund.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Cilostazol (CIL), a BCS class II antiplatelet aggregation and vasodilator agent, is used for cerebrovascular diseases to minimize blood–brain barrier dysfunction, white matter-lesion formation, and motor deficits. The current work aimed to develop and optimize cilostazol-loaded spanlastics (CIL-SPA) for nose-to-brain delivery to overcome the low solubility and absorption, the first pass-metabolism, and the adverse effects. The optimal CIL-SPA formulation was loaded into Phytagel® (SPA-PG), Poloxamer-407 (SPA-P407), and chitosan (SPA-CS) gel bases and characterized in terms of colloidal properties, encapsulation efficiency (EE%), mucoadhesive properties, and biopharmaceutical aspects. The developed in situ gelling formulations showed a 99%). All formulations met the droplet size-distribution criteria of nasal requirements (

Schlagwörter

Stichwörter der Autor:innen

Phytagel®Poloxamer-407chitosancilostazolin situ gelspanlastics

Autor:innen und Institutionen

  • Institute of Pharmaceutical Technology and Regulatory Affairs, Faculty of Pharmacy, University of Szeged, Eötvös Str. 6, H-6720 Szeged, Hungary.
  • Institute of Pharmacodynamics and Biopharmacy, Faculty of Pharmacy, University of Szeged, Eötvös Str. 6, H-6720 Szeged, Hungary.
  • Directorate of Drug Substance Development, Egis Pharmaceuticals Plc., Keresztúri Str. 30-38, H-1106 Budapest, Hungary.
  • Department of Pharmaceutical Chemistry, Semmelweis University, Hőgyes Endre Str. 9, H-1092 Budapest, Hungary.
  • Center for Pharmacology and Drug Research & Development, Semmelweis University, Üllői Str. 26, H-1085 Budapest, Hungary.

ORCID-Profile: Maryana Salamah, Mária Budai-Szűcs, Bence Sipos, Balázs Volk, Gábor Katona, György Tibor Balogh, Ildikó Csóka

Förderung

  • Ministry of Innovation and Technology of Hungary from the National Research, Development, and Innovation Fund

Zitieren

APA

Salamah, M., Budai-Szűcs, M., Sipos, B., Volk, B., Katona, G., Balogh, G. T., & Csóka, I. (2025). Development and Characterization of In Situ Gelling Nasal Cilostazol Spanlastics. Gels, 11(2), 82. https://doi.org/10.3390/gels11020082

Vancouver

Salamah M, Budai-Szűcs M, Sipos B, Volk B, Katona G, Balogh GT, et al. Development and Characterization of In Situ Gelling Nasal Cilostazol Spanlastics. Gels. 2025;11(2):82. doi:10.3390/gels11020082

BibTeX
@article{Salamah2025,
  author = {Salamah, Maryana and Budai-Szűcs, Mária and Sipos, Bence and Volk, Balázs and Katona, Gábor and Balogh, György Tibor and Csóka, Ildikó},
  title = {Development and Characterization of In Situ Gelling Nasal Cilostazol Spanlastics},
  journal = {Gels},
  year = {2025},
  volume = {11},
  number = {2},
  pages = {82},
  doi = {10.3390/gels11020082}
}
Kostenlos starten →